Clinical Fellowships
This grant funds U.S. academic fellowships to train physicians in the diagnosis, treatment, and research of Transthyretin-mediated Amyloidosis (ATTR) through robust, multidisciplinary clinical education.
Funder: Alnylam Pharmaceuticals
Due Dates: August 28, 2026 (Clinical Fellowships full application submission)
Funding Amounts: Up to $95,000 per institution for a one-year fellowship; funds cover salary and benefits only.
Summary: Supports U.S. academic clinical fellowship programs to train physicians in Transthyretin-mediated Amyloidosis (ATTR) through education, research, and multidisciplinary care.
Description
Alnylam Pharmaceuticals’ Clinical Fellowships provide financial support to U.S. academic healthcare organizations for educational clinical programs focused on Transthyretin-mediated Amyloidosis (ATTR Amyloidosis). The goal is to foster the training and mentorship of physicians in the diagnosis, treatment, and research of ATTR, encouraging multidisciplinary collaboration to improve early recognition, optimize treatment, and accelerate the translation of emerging science into high-quality, patient-centered care. Funding is intended for fellow salary and benefits, and programs must demonstrate robust curricula and interdisciplinary educational opportunities.
